Curation
Accueil
Racine
Curation
Exploration
Accueil
Racine
Accueil
Racine

Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.

Identifieur interne : 001A88 ( Main/Curation ); précédent : 001A87; suivant : 001A89

Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.

Auteurs : David R. Strayer ; Robert Dickey ; William A. Carter [États-Unis]

Source :

RBID : pubmed:25019238

Descripteurs français

English descriptors

Abstract

A novel coronavirus (MERS-CoV) related to SARS-CoV recently emerged in the Middle East causing more than 400 deaths with a mortality rate of about 30%, much higher than SARS-CoV. Both viruses target epithelial cells in the respiratory tract, although utilizing different cellular receptors. Because of the sporadic nature of the MERS outbreak and difficulty in collecting randomized, controlled clinical data, the objective of this review was to focus on published in vitro and in vivo drug sensitivity data using both cell lines and available animal models of SARS/MERS CoV infection. Determination of drug activity was based on achievable serum levels in humans relative to in vitro IC50 (50% inhibitory concentration) or EC50 (50% effective concentration) drug concentrations. The most active drugs against SARS/MERS CoV at clinically achievable serum levels were type I interferons and a TLR3 agonist, interferon inducer/activator.

DOI: 10.2174/1871526514666140713152858
PubMed: 25019238

Links toward previous steps (curation, corpus...)

Links to Exploration step

pubmed:25019238

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.</title>
<author>
<name sortKey="Strayer, David R" sort="Strayer, David R" uniqKey="Strayer D" first="David R" last="Strayer">David R. Strayer</name>
</author>
<author>
<name sortKey="Dickey, Robert" sort="Dickey, Robert" uniqKey="Dickey R" first="Robert" last="Dickey">Robert Dickey</name>
</author>
<author>
<name sortKey="Carter, William A" sort="Carter, William A" uniqKey="Carter W" first="William A" last="Carter">William A. Carter</name>
<affiliation wicri:level="2">
<nlm:affiliation>Hemispherx Biopharma, Inc., Philadelphia, PA 19103, USA. david.strayer@hemispherx.net.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hemispherx Biopharma, Inc., Philadelphia, PA 19103</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25019238</idno>
<idno type="pmid">25019238</idno>
<idno type="doi">10.2174/1871526514666140713152858</idno>
<idno type="wicri:Area/PubMed/Corpus">001914</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001914</idno>
<idno type="wicri:Area/PubMed/Curation">001914</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001914</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001746</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001746</idno>
<idno type="wicri:Area/Ncbi/Merge">000E34</idno>
<idno type="wicri:Area/Ncbi/Curation">000E34</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E34</idno>
<idno type="wicri:Area/Main/Merge">001A95</idno>
<idno type="wicri:Area/Main/Curation">001A88</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.</title>
<author>
<name sortKey="Strayer, David R" sort="Strayer, David R" uniqKey="Strayer D" first="David R" last="Strayer">David R. Strayer</name>
</author>
<author>
<name sortKey="Dickey, Robert" sort="Dickey, Robert" uniqKey="Dickey R" first="Robert" last="Dickey">Robert Dickey</name>
</author>
<author>
<name sortKey="Carter, William A" sort="Carter, William A" uniqKey="Carter W" first="William A" last="Carter">William A. Carter</name>
<affiliation wicri:level="2">
<nlm:affiliation>Hemispherx Biopharma, Inc., Philadelphia, PA 19103, USA. david.strayer@hemispherx.net.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hemispherx Biopharma, Inc., Philadelphia, PA 19103</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Infectious disorders drug targets</title>
<idno type="eISSN">2212-3989</idno>
<imprint>
<date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (blood)</term>
<term>Cell Line</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Dosage Calculations</term>
<term>Humans</term>
<term>Immunologic Factors (administration & dosage)</term>
<term>Immunologic Factors (blood)</term>
<term>Interferons (administration & dosage)</term>
<term>Interferons (blood)</term>
<term>Microbial Sensitivity Tests</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term>
<term>Respiratory Mucosa (drug effects)</term>
<term>Respiratory Mucosa (virology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (sang)</term>
<term>Calcul des posologies</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term>
<term>Facteurs immunologiques (administration et posologie)</term>
<term>Facteurs immunologiques (sang)</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Interférons (administration et posologie)</term>
<term>Interférons (sang)</term>
<term>Lignée cellulaire</term>
<term>Modèles animaux de maladie humaine</term>
<term>Muqueuse respiratoire ()</term>
<term>Muqueuse respiratoire (virologie)</term>
<term>Relation dose-effet des médicaments</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antiviral Agents</term>
<term>Immunologic Factors</term>
<term>Interferons</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antiviral Agents</term>
<term>Immunologic Factors</term>
<term>Interferons</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Antiviraux</term>
<term>Facteurs immunologiques</term>
<term>Interférons</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Respiratory Mucosa</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en">
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr">
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Antiviraux</term>
<term>Facteurs immunologiques</term>
<term>Interférons</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Infections à coronavirus</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Infections à coronavirus</term>
<term>Muqueuse respiratoire</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Coronavirus Infections</term>
<term>Respiratory Mucosa</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cell Line</term>
<term>Disease Models, Animal</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Dosage Calculations</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Calcul des posologies</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Modèles animaux de maladie humaine</term>
<term>Muqueuse respiratoire</term>
<term>Relation dose-effet des médicaments</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">A novel coronavirus (MERS-CoV) related to SARS-CoV recently emerged in the Middle East causing more than 400 deaths with a mortality rate of about 30%, much higher than SARS-CoV. Both viruses target epithelial cells in the respiratory tract, although utilizing different cellular receptors. Because of the sporadic nature of the MERS outbreak and difficulty in collecting randomized, controlled clinical data, the objective of this review was to focus on published in vitro and in vivo drug sensitivity data using both cell lines and available animal models of SARS/MERS CoV infection. Determination of drug activity was based on achievable serum levels in humans relative to in vitro IC50 (50% inhibitory concentration) or EC50 (50% effective concentration) drug concentrations. The most active drugs against SARS/MERS CoV at clinically achievable serum levels were type I interferons and a TLR3 agonist, interferon inducer/activator. </div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A88 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001A88 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:25019238
   |texte=   Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:25019238" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021